spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cladribine 

 HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 13 Oct 2020
Chord Therapeutics launches with USD 16 million Series A financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 5 Sep 2017
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Aug 2017
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Sep 2011
TrovaGene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia
Diagnostics Licensing Oncology
 HSMN NewsFeed - 21 Jan 2010
Two-Year Results From CLARITY Study with Cladribine Tablets in Multiple Sclerosis Published in The New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Jan 2009
Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Sep 2008
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jun 2008
Merck Serono's Rebif(R) Celebrates 10th Anniversary
BIopharmaceuticals Neurology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Dec 2006
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Sep 2006
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
Biopharmaceuticals Neurology Regulatory
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
cladribine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.